Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 1998

View Archived Issues

Protein Design Labs and Genentech enter agreement for antibody patents

Gatifloxacin highlighted at ICAAC as an effective new treatment for pneumonia

FDA approves Serevent Diskus for maintenance treatment of pediatric asthma

Spotlight on antifungal agents for treating aspergillosis

New treatment for CMV retinitis in the pipeline at Roche

Development status updated for 3M's imiquimod analogue R-848

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Abbott initiates phase II trials with ABT-606

Spotlight on drug therapy for hepatitis

Cell Genesys receives milestone payment from HMR for GA-EPO agreement

University of Pittsburgh recruits patients for Somnoplasty clinical trial

Data suggest Ossigel significantly accelerates fracture healing

Synthesis and activity of new antifungal agents reported by Nihon Nohyaku

Wakamoto discovers natural substances for Alzheimer's disease

Rovi introduces LMW heparin in Spain

New agents for cytokine- and/or CAM-mediated disorders disclosed by Pfizer

Chalcone derivatives show potential in the treatment of leishmaniasis

Centocor launches new treatment for Crohn's disease

Leflunomide market introduction announced

rPAF-AH shows neuroprotective activity in hippocampal neurons

Emory University issued U.S. patent for FTC compound

Alza to acquire Sequus

FDA committee recommends approval of Epivir-HBV

Long-acting fluorine-containing prostaglandins for ocular diseases

ADIR presents two new series of ellipticine derivatives with improved profiles

Nonpeptide BK antagonist effective in guinea pig models of allergy

Melatonin neuroprotective in a mouse TBI model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...